Neo-Bionica

Neo-Bionica operates at the intersection of neurotechnology, medical-device manufacturing, and clinical development. Its position is differentiated less by a named commercial product than by the breadth of its delivery model: the company supports early-stage concepts through systems engineering, prototyping, device integration, regulatory readiness, manufacturing establishment, and First-in-Human preparation. Website materials identify dedicated neurotechnology and implantable-device expertise, an ISO 13485-certified quality system, ISO-7 cleanroom facilities, and a location within St. Vincent’s Hospital Melbourne. These features give Neo-Bionica a practical bridge between academic or clinical invention and a manufacturable Class III implantable device. Relative to general contract engineering firms, its stated specialization in neural interfaces, implantable power systems, electrodes, embedded firmware, and hermetic packaging suggests a narrower but deeper focus. Its USD 5.16 million in disclosed funding and 11–50 employee range indicate a specialist platform rather than a scaled device manufacturer.

Neo-Bionica’s trajectory shows a transition from an early-stage neurotechnology venture toward a more structured product-realization and manufacturing partner. Founded in 2021, it reached a major financing inflection point on May 16, 2024 with a USD 5 million seed investment from Breakthrough Victoria. A further grant announced on Jul 30, 2025 added approximately USD 161,145, bringing disclosed funding to USD 5,161,145. The company subsequently recorded the appointment of Jovi Sia as Head of Finance on Sep 1, 2025, a functional expansion consistent with managing grant requirements, manufacturing operations, and future clinical-development activity. Its stated capabilities cover the full development chain, including neural-interface modelling, Sim4Life simulation, custom microfabrication, laser seam welding, hermeticity testing, embedded systems, and ISO-7 rapid prototyping. However, the public record does not establish employee-count growth, product commercialization dates, regulatory submissions, or completed clinical milestones, limiting confidence about the pace from funded development to recurring revenue.